Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment

Schizophrenia Research

Volumn 100, Issue 1-3, 2008, Pages 252-260

  Barr, Alasdair M ^a   Procyshyn, Ric M ^b,c   Hui, Philip ^b   Johnson, Joy L ^c   Honer, William G ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RIVERVIEW HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotic; Cigarette; Motivation; Nicotine dependency; Schizophrenia; Smoking

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; NICOTINE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NERVE STIMULATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUESTIONNAIRE; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SELF REPORT; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; VALIDITY;

ANTIPSYCHOTIC AGENTS; BEHAVIOR, ADDICTIVE; COMMUNITY MENTAL HEALTH SERVICES; CONTROL GROUPS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SLEEP; SMOKING; TOBACCO USE DISORDER;

EID: 39949083953     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.11.027     Document Type: Article

References (53)

1. Addington J., el-Guebaly N., Addington D., and Hodgins D. Readiness to stop smoking in schizophrenia. Can. J. Psychiatry 42 (1997) 49-52
2. Anfang M.K., and Pope Jr. H.G. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl) 134 (1997) 153-156
3. Barak Y., Achiron A., Mandel M., Mirecki I., and Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer 104 (2005) 2817-2821
4. Barnes M., Lawford B.R., Burton S.C., Heslop K.R., Noble E.P., Hausdorf K., and Young R.M. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?. Aust. N. Z. J. Psychiatry 40 (2006) 575-580
5. Bezchlibnyk-Butler K.Z., and Jeffries J.J. Clinical Handbook of Psychotropic Drugs. 14th edition (2004), Hogrefe & Huber publishers, Toronto
6. Bhatnagar S., Costall B., and Smythe J.W. Hippocampal cholinergic blockade enhances hypothalamic-pituitary-adrenal responses to stress. Brain Res. 766 (1997) 244-248
7. de Leon J., Becona E., Gurpegui M., Gonzalez-Pinto A., and Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. J. Clin. Psychiatry 63 (2002) 812-816
8. de Leon J., Diaz F.J., Rogers T., Browne D., and Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr. Res. 56 (2002) 47-54
9. de Leon J., Diaz F.J., Josiassen R.C., Cooper T.B., and Simpson G.M. Does clozapine decrease smoking?. Prog. Neuro-psychopharmacol. Biol. Psychiatry 29 (2005) 757-762
10. de Leon J., Diaz F.J., Aguilar M.C., Jurado D., and Gurpegui M. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophr. Res. 86 (2006) 256-268
11. El-Guebaly N., Cathcart J., Currie S., Brown D., and Gloster S. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatr. Serv. 53 (2002) 1617-1622
12. Ellinas P.A., Rosner F., and Jaume J.C. Symptomatic hyponatremia associated with psychosis, medications, and smoking. J. Natl. Med. Assoc. 85 (1993) 135-141
13. Fonder M.A., Sacco K.A., Termine A., Boland B.S., Seyal A.A., Dudas M.M., Vessicchio J.C., and George T.P. Smoking cue reactivity in schizophrenia: effects of a nicotinic receptor antagonist. Biol. Psychiatry 57 (2005) 802-808
14. Forchuk C., Norman R., Malla A., Martin M.L., McLean T., Cheng S., Diaz K., McIntosh E., Rickwood A., Vos S., and Gibney C. Schizophrenia and the motivation for smoking. Perspect. Psychiatr. Care 38 (2002) 41-49
15. George T.P., Sernyak M.J., Ziedonis D.M., and Woods S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. J. Clin. Psychiatry 56 (1995) 344-346
16. George T.P., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., and Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am. J. Psychiatry 157 (2000) 1835-1842
17. Glynn S.M., and Sussman S. Why patients smoke. Hosp. Community Psychiatry 41 (1990) 1027-1028
18. Goff D.C., Henderson D.C., and Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am. J. Psychiatry 149 (1992) 1189-1194
19. Gurpegui M., Martinez-Ortega J.M., Jurado D., Aguilar M.C., Diaz F.J., and de Leon J. Subjective effects and the main reason for smoking in outpatients with schizophrenia: a case-control study. Compr. Psychiatry 48 (2007) 186-191
20. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict 86 (1991) 1119-1127
21. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
22. Horan W.P., Brown S.A., and Blanchard J.J. Social anhedonia and schizotypy: the contribution of individual differences in affective traits, stress, and coping. Psychiatry Res. 149 (2007) 147-156
23. Kitabayashi Y., Narumoto J., Shibata K., Nakamae T., Kamei J., Sano K., Oka S., Yamashita T., Kitabayashi M., and Fukui K. Effect of institutional smoking prohibition on Japanese inpatients with chronic schizophrenia. Nihon Arukoru Yakubutsu Igakkai Zasshi 41 (2006) 128-133
24. Kumari V., and Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 29 (2005) 1021-1034
25. Levin E.D., Wilson W., Rose J.E., and McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15 (1996) 429-436
26. Lyon E.R. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr. Serv. 50 (1999) 1346-1350
27. Marx C.E., McIntosh E., Wilson W.H., and McEvoy J.P. Mecamylamine increases cigarette smoking in psychiatric patients. J. Clin. Psychopharmacol. 20 (2000) 706-707
28. McEvoy J., Freudenreich O., McGee M., VanderZwaag C., Levin E., and Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol. Psychiatry 37 (1995) 550-552
29. McEvoy J.P., Freudenreich O., Levin E.D., and Rose J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 119 (1995) 124-126
30. Minzenberg M.J., Poole J.H., Benton C., and Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry 161 (2004) 116-124
31. Mulsant B.H., Gharabawi G.M., Bossie C.A., Mao L., Martinez R.A., Tune L.E., Greenspan A.J., Bastean J.N., and Pollock B.G. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J. Clin. Psychiatry 65 (2004) 1708-1714
32. Naidoo U., Goff D.C., and Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2 28 Suppl (2003) 97-108
33. Peretti C.S., Danion J.M., Kauffmann-Muller F., Grange D., Patat A., and Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl) 131 (1997) 329-338
34. Piko B.F., Wills T.A., and Walker C. Motives for smoking and drinking: country and gender differences in samples of Hungarian and US high school students. Addict. Behav. 32 (2007) 2087-2098
35. Pomerleau O.F., and Pomerleau C.S. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neurosci. Biobehav. Rev. 8 (1984) 503-513
36. Pomerleau C.S., Pomerleau O.F., Flessland K.A., and Basson S.M. Relationship of Tridimensional Personality Questionnaire scores and smoking variables in female and male smokers. J. Subst. Abuse 4 (1992) 143-154
37. Procyshyn R.M., Ihsan N., and Thompson D. A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. Int. Clin. Psychopharmacol. 16 (2001) 291-294
38. Remington G., and Chong S.A. Conventional versus novel antipsychotics: changing concepts and clinical implications. J. Psychiatry Neurosci. 24 (1999) 431-441
39. Riley E.M., McGovern D., Mockler D., Doku V.C., O.C. S., Fannon D.G., Tennakoon L., Santamaria M., Soni W., Morris R.G., and Sharma T. Neuropsychological functioning in first-episode psychosis-evidence of specific deficits. Schizophr. Res. 43 (2000) 47-55
40. Ritsner M., Gibel A., and Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Qual. Life Res. 15 (2006) 515-526
41. Russell M.A.H., Peto J., and Patel U.A. The classification of smoking by factorial structure of motives. J. R. Stat. Soc., A 137 (1974) 313-342
42. Saeedi H., Remington G., and Christensen B.K. The Impact of Haloperidol, a Selective Dopamine D2 Antagonist, on Cognition, Motor Movements and Mood (2004), Harvey Stancer Research Day University of Toronto
43. Saeedi H., Remington G., and Christensen B.K. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr. Res. 85 (2006) 222-231
44. Smith G.L. Schizophrenia, smoking, and boredom. Am. J. Psychiatry 153 (1996) 583-584
45. Smythe J.W., Murphy D., Bhatnagar S., Timothy C., and Costall B. Muscarinic antagonists are anxiogenic in rats tested in the black-white box. Pharmacol. Biochem. Behav. 54 (1996) 57-63
46. Steinberg M.L., Williams J.M., Steinberg H.R., Krejci J.A., and Ziedonis D.M. Applicability of the Fagerstrom Test for Nicotine Dependence in smokers with schizophrenia. Addict. Behav. 30 (2005) 49-59
47. Tate J.C., Pomerleau C.S., and Pomerleau O.F. Pharmacological and non-pharmacological smoking motives: a replication and extension. Addiction 89 (1994) 321-330
48. Todman M. Boredom and psychotic disorders: cognitive and motivational issues. Psychiatry 66 (2003) 146-167
49. Ucok A., Polat A., Bozkurt O., and Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin. Neurosci. 58 (2004) 434-437
50. Voruganti L., and Awad A.G. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171 (2004) 121-132
51. Weinberger A.H., Reutenauer E.L., Allen T.M., Termine A., Vessicchio J.C., Sacco K.A., Easton C.J., McKee S.A., and George T.P. Reliability of the Fagerstrom Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia. Drug Alcohol Depend. 86 (2007) 278-282
52. Yang Y.K., Nelson L., Kamaraju L., Wilson W., and McEvoy J.P. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 27 (2002) 684-686
53. Yang Y.K., McEvoy J.P., Wilson W.H., Levin E.D., and Rose J.E. Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. Schizophr. Res. 60 (2003) 9-12